A Open-label, Randomized, Parallel, Phase III Trial to Evaluate the Efficacy and Safety of Genexol-PM Compared to Genexol (Conventional Paclitaxel With Cremorphor EL) in Subjects With Recurrent or Metastatic Breast Cancer

Trial Profile

A Open-label, Randomized, Parallel, Phase III Trial to Evaluate the Efficacy and Safety of Genexol-PM Compared to Genexol (Conventional Paclitaxel With Cremorphor EL) in Subjects With Recurrent or Metastatic Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Samyang Biopharmaceuticals Corporation
  • Most Recent Events

    • 27 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2013 Interim results presented at the 4th International Nanomedicine Conference in Sydney Australia, according to a media release from Sorrento Therapeutics and IGDRASOL.
    • 13 May 2013 Comprehensive data analyses will be presented at future medical conferences, according to a Sorrento Therapeutics and IgDraSol media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top